Plasma cell leukemia: genomic features and their potential relevance for exploring clinical actionability. Blood Adv 2026 Feb 24;10(4):1400-1404
Date
12/18/2025Pubmed ID
41411484Pubmed Central ID
PMC12927052DOI
10.1182/bloodadvances.2025018342Scopus ID
2-s2.0-105030120191 (requires institutional sign-in at Scopus site)Abstract
Plasma cell leukemia (PCL) is rare and aggressive. Plasma cells from patients with PCL were examined using next-generation sequencing (NGS). We compared NGS data from 18 patients with PCL (peripheral blood, n = 10; bone marrow, n = 8) and 1742 multiple myeloma (MM) samples. Mutations of TP53, CCND1, and KRAS were commonly observed in both diseases. Alterations in DIS3 (17% vs 1%), CCND2 (22% vs 15%), PIK3R1 (6% vs 0%), and MAP3K1 (6% vs 2%) were more common in PCL than in MM (P< .05). Translocations occurred in 11 (61.1%) patients with PCL; IGH::CCND1 and IGH::MYC were more frequent in PCL than in MM (22% vs 14%, P = not significant and 11% vs 1%, P< .05, respectively). Druggable aberrations in BRAF, CCND1, PIK3R1, and RAS may be targeted in biomarker-driven therapeutic clinical trials.
Author List
Mohan M, Danziger N, Akhtar OS, Narra R, Pasquini MC, Radhakrishnan S, Dhakal B, D'Souza A, Lin D, Ho C, Kurzrock RAuthors
Anita D'Souza MD Professor in the Medicine department at Medical College of WisconsinBinod Dhakal MBBS, MD Professor in the Medicine department at Medical College of Wisconsin
Ravi Kishore Narra MD Assistant Professor in the Medicine department at Medical College of Wisconsin
Sabarinath Venniyil Radhakrishnan MD Assistant Professor in the Medicine department at Medical College of Wisconsin
MESH terms used to index this publication - Major topics in bold
AdultAged
Aged, 80 and over
Biomarkers, Tumor
Female
Genomics
High-Throughput Nucleotide Sequencing
Humans
Leukemia, Plasma Cell
Male
Middle Aged
Mutation
